We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Flushing the quarry

2 May 2011 By Robert Cyran

The drugmaker hoped to snaffle up rival Cephalon in weeks with a proxy fight. Valeant made it clear it attached little value to the target’s pipeline and wouldn’t get in a bidding war. That left plenty of room for white knight Teva to swoop in for Cephalon with a $6.8 bln offer.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)